Quantitative wearable sensors for objective assessment of Parkinson's disease
W Maetzler, J Domingos, K Srulijes… - Movement …, 2013 - Wiley Online Library
There is a rapidly growing interest in the quantitative assessment of Parkinson's disease
(PD)‐associated signs and disability using wearable technology. Both persons with PD and …
(PD)‐associated signs and disability using wearable technology. Both persons with PD and …
Therapies in Parkinson's disease
J Jankovic, W Poewe - Current opinion in neurology, 2012 - journals.lww.com
Numerous clinical trials have provided evidence that health-related quality of life can be
substantially improved with early diagnosis and institution of exercise and other physical …
substantially improved with early diagnosis and institution of exercise and other physical …
[HTML][HTML] Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis
G DeMaagd, A Philip - Pharmacy and therapeutics, 2015 - ncbi.nlm.nih.gov
Parkinson’s Disease and Its Management - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search …
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search …
Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life
A Manson, P Stirpe, A Schrag - Journal of Parkinson's disease, 2012 - content.iospress.com
Levodopa-induced dyskinesias (LID) belong to the most common dose-limiting adverse
effects of levodopa therapy.“Peak-dose” LID occur with the maximum effect of …
effects of levodopa therapy.“Peak-dose” LID occur with the maximum effect of …
Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia
D Vijayakumar, J Jankovic - Drugs, 2016 - Springer
Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly
chorea, dystonia, stereotypies, and akathisia. Levodopa-induced dyskinesia (LID) is one of …
chorea, dystonia, stereotypies, and akathisia. Levodopa-induced dyskinesia (LID) is one of …
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial
Objective: The AMANDYSK trial was designed to assess long-term efficacy of chronic
treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced …
treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced …
Management of motor and non-motor symptoms in Parkinson's disease
F Sprenger, W Poewe - CNS drugs, 2013 - Springer
Parkinson's disease (PD) is the second most common neurodegenerative disorder that
affects approximately 1% of people over the age of 60 years. Accurate diagnosis and …
affects approximately 1% of people over the age of 60 years. Accurate diagnosis and …
Motor complications of dopaminergic medications in Parkinson's disease
Motor complications are a consequence of the chronic treatment of Parkinson's disease (PD)
and include motor fluctuations (wearing-off phenomenon) and levodopa-induced …
and include motor fluctuations (wearing-off phenomenon) and levodopa-induced …
l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus
The molecular basis of priming for l-DOPA-induced dyskinesias in Parkinson's disease (PD),
which depends on the indirect pathway of motor control, is not known. In rodents, the indirect …
which depends on the indirect pathway of motor control, is not known. In rodents, the indirect …
Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate
M Beaudoin-Gobert, J Epinat, E Metereau, S Duperrier… - Brain, 2015 - academic.oup.com
Abstract Serotonergic (5-HT) neurons degenerate in Parkinson's disease. To determine the
role of this 5-HT injury—besides the dopaminergic one in the parkinsonian symptomatology …
role of this 5-HT injury—besides the dopaminergic one in the parkinsonian symptomatology …